Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
R. Nandan M.D. Incorporated |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00005825 |
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have stage IIIB or stage IV non-small cell lung cancer.
Condition | Intervention | Phase |
---|---|---|
Lung Cancer |
Drug: cisplatin Drug: mitomycin C Drug: tretinoin Drug: vinorelbine ditartrate |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment |
Official Title: | Trans Retinoic Acid (Vesanoid) With Chemotherapy in Non-Small Cell Lung Cancer |
Study Start Date: | September 1998 |
OBJECTIVES:
OUTLINE: Patients receive tretinoin orally twice daily for 4 days starting days 1 and 8; cisplatin IV over 2 hours and vinorelbine IV on days 1 and 8; and mitomycin IV (courses 1 and 3) on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
Patients are followed for survival.
PROJECTED ACCRUAL: At total of 15-46 patients will be accrued for this study.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
PATIENT CHARACTERISTICS:
Age:
Performance status:
Life expectancy:
Hematopoietic:
Hepatic:
Renal:
Cardiovascular:
Other:
PRIOR CONCURRENT THERAPY:
Biologic therapy:
Chemotherapy:
Endocrine therapy:
Radiotherapy:
Surgery:
United States, California | |
Rajendra Prasad M.D., Inc. | |
Lakewood, California, United States, 90712 |
Study Chair: | Raghu Nandan, MD | R. Nandan M.D. Incorporated |
Study ID Numbers: | CDR0000067837, NANDAN-VES-024, NCI-V00-1587 |
Study First Received: | June 2, 2000 |
Last Updated: | July 23, 2008 |
ClinicalTrials.gov Identifier: | NCT00005825 History of Changes |
Health Authority: | United States: Federal Government |
stage IIIB non-small cell lung cancer stage IV non-small cell lung cancer |
Thoracic Neoplasms Vinblastine Antimitotic Agents Mitomycins Carcinoma Anti-Bacterial Agents Vinorelbine Respiratory Tract Diseases Cisplatin Lung Neoplasms |
Lung Diseases Tubulin Modulators Mitomycin Non-small Cell Lung Cancer Tretinoin Antineoplastic Agents, Phytogenic Alkylating Agents Carcinoma, Non-Small-Cell Lung Neoplasms, Glandular and Epithelial |
Thoracic Neoplasms Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Vinblastine Antibiotics, Antineoplastic Neoplasms by Site Respiratory Tract Diseases Lung Neoplasms Therapeutic Uses Mitomycin Alkylating Agents Nucleic Acid Synthesis Inhibitors Respiratory Tract Neoplasms |
Neoplasms by Histologic Type Mitosis Modulators Enzyme Inhibitors Antimitotic Agents Pharmacologic Actions Carcinoma Neoplasms Vinorelbine Lung Diseases Tubulin Modulators Carcinoma, Non-Small-Cell Lung Antineoplastic Agents, Phytogenic Neoplasms, Glandular and Epithelial |